Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of vaccinia virus in the treatment of metastatic malignant melanoma.

Literature DB >> 4913781

Use of vaccinia virus in the treatment of metastatic malignant melanoma.

I Hunter-Craig, K A Newton, G Westbury, B W Lacey.

Abstract

Of 19 patients with proved metastases from malignant melanoma treated by inoculations of smallpox vaccine, intradermal deposits disappeared completely in six out of ten cases. Five of these remained well 2 to 22 months after initial treatment. The response was limited strictly to the site of inoculation. The mechanism of action of vaccinia virus in malignant melanoma is not clear.

Entities: Disease Species

Mesh：

Substances：
Smallpox Vaccine

Year: 1970 PMID： 4913781 PMCID： PMC1700360 DOI： 10.1136/bmj.2.5708.512

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

5 in total

1. VITILIGO IN A CASE OF VACCINIA VIRUS-TREATED MELANOMA.

Authors: K H BURDICK; W A HAWK
Journal: Cancer Date: 1964-06 Impact factor: 6.860

2. The experimental local therapy of cutaneous metastases of malignant melanoblastomas with cow pox vaccine or colcemid (demecolcine or omaine).

Authors: J C BELISARIO; G W MILTON
Journal: Aust J Dermatol Date: 1961-12

3. Protective activity of fractions of tubercle bacilli against isologous tumours in mice.

Authors: D W WEISS; R S BONHAG; K B DEOME
Journal: Nature Date: 1961-06-03 Impact factor: 49.962

4. The role of the reticuloendothelial system in the host reaction to neoplasia.

Authors: L J OLD; B BENACERRAF; D A CLARKE; E A CARSWELL; E STOCKERT
Journal: Cancer Res Date: 1961-10 Impact factor: 12.701

5. The limited role of attenuated smallpox virus in the management of advanced malignant melanoma.

Authors: G W Milton; M M Brown
Journal: Aust N Z J Surg Date: 1966-05

5 in total

13 in total

6. Immune responses of DBA/2 mice bearing melanoma tumors: cell-mediated immune responses after challenge with vaccinia virus.

Authors: J A Byrne; M Soloski; J A Holowczak
Journal: Cancer Immunol Immunother Date: 1983 Impact factor: 6.968

10. Role of "lymphotoxin" in the local anti-tumour action associated with inflammation caused by delayed hypersensitivity responses or intralesional BCG. I. Variations in response of different syngeneic mouse tumours.

Authors: I B Parr; L E Jackson; P Alexander
Journal: Br J Cancer Date: 1983-09 Impact factor: 7.640

Use of vaccinia virus in the treatment of metastatic malignant melanoma.

1. VITILIGO IN A CASE OF VACCINIA VIRUS-TREATED MELANOMA.

2. The experimental local therapy of cutaneous metastases of malignant melanoblastomas with cow pox vaccine or colcemid (demecolcine or omaine).

3. Protective activity of fractions of tubercle bacilli against isologous tumours in mice.

4. The role of the reticuloendothelial system in the host reaction to neoplasia.

5. The limited role of attenuated smallpox virus in the management of advanced malignant melanoma.

1. Strategy in the management of melanoma.

Review 2. The role of immunotherapy in the management of patients with malignant melanoma.

Review 3. Infectious diseases: annual review of significant publications.

4. [Immunologic analysis of tyrosinase in malignant melanoma, nevi and clinically normal skin].

5. Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials.

6. Immune responses of DBA/2 mice bearing melanoma tumors: cell-mediated immune responses after challenge with vaccinia virus.

Review 7. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

8. Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer.

Review 9. Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.

10. Role of "lymphotoxin" in the local anti-tumour action associated with inflammation caused by delayed hypersensitivity responses or intralesional BCG. I. Variations in response of different syngeneic mouse tumours.